Could AI reduce healthcare waste? Approach of online retailers could provide clues

Could AI reduce healthcare waste? Approach of online retailers could provide clues

When Amazon envisioned Alexa, an AI-powered, voice-activated customer recommendation system, it was a feat that required machine learning and massive amounts of data to provide answers to conversational queries quickly, even in a noisy environment. Now, the same data analysis

Read More Could AI reduce healthcare waste? Approach of online retailers could provide clues

Survey: HR administrators, employees disagree on mental health coverage

Sad face depression

Since the start of the pandemic, many companies looked for ways to bolster mental health coverage, but there’s still a disconnect between HR administrators and employees, according to a recent survey conducted by mental health startup Lyra Health. About half

Read More Survey: HR administrators, employees disagree on mental health coverage

Meet Circulo, the insurtech firm on a mission to disrupt Medicaid managed care

Meet Circulo, the insurtech firm on a mission to disrupt Medicaid managed care

The insurtech market, which is characterized by fierce competition, recently saw a new entrant: Circulo. Co-founded by Sean Lane — CEO of another health tech startup Olive — the new Medicaid managed care company launched last month with $50 million

Read More Meet Circulo, the insurtech firm on a mission to disrupt Medicaid managed care

Payers team up to vaccinate older Americans in underserved communities  

Merck drops out of the Covid-19 vaccine race after subpar data

A group of health insurers are joining forces to help get older Americans in underserved communities vaccinated with the Covid-19 vaccine. Members of America’s Health Insurance Plans, a national payer association, and Blue Cross Blue Shield Association, a federation of

Read More Payers team up to vaccinate older Americans in underserved communities  

Amgen’s $1.9B Five Prime deal adds to cancer drug pipeline and Asia strategy

Amgen

  Amgen, which is looking to bolster its cancer drug pipeline and build its presence in Asia, is acquiring Five Prime Therapeutics in a $1.9 billion deal that checks off both goals. On Thursday, Amgen announced it has agreed to

Read More Amgen’s $1.9B Five Prime deal adds to cancer drug pipeline and Asia strategy

Generics companies face risk as SCOTUS questions patent tribunal’s constitutionality

Generics companies face risk as SCOTUS questions patent tribunal’s constitutionality

U.S. Supreme Court justices on Monday questioned lawyers for Arthrex Inc., Smith & Nephew and the U.S. government on the constitutionality of the country’s patent tribunal, in a case that could eradicate a key tool for generic and technology companies

Read More Generics companies face risk as SCOTUS questions patent tribunal’s constitutionality

How digital health impacts the development and adoption of cancer immunotherapies

How digital health impacts the development and adoption of cancer immunotherapies

Essential to the future of cancer immunotherapies is a digital health infrastructure that can support reliable, secure and compliant data collection from disparate systems and devices. As more and more immuno-oncology (IO) treatments come to market, biopharma will require data

Read More How digital health impacts the development and adoption of cancer immunotherapies

Takeda to pay Ovid $196M for full rights to Phase 3-ready epilepsy drug

brain

When Takeda Pharmaceutical and Ovid Therapeutics began working together four years ago, the partners aimed to share in the development of a drug with the potential to treat rare forms of epilepsy. The partners are ending the alliance, but Takeda

Read More Takeda to pay Ovid $196M for full rights to Phase 3-ready epilepsy drug

FDA calls out Brainstorm’s ALS stem cell therapy, says data don’t show benefit

FDA sign, headquarters

  The FDA almost never reveals its thinking about a drug prior to issuing a regulatory decision, and when that decision is a rejection the letter to the company is always confidential. Brainstorm Cell Therapeutics hasn’t even submitted its amyotrophic

Read More FDA calls out Brainstorm’s ALS stem cell therapy, says data don’t show benefit

Hillrom faces lawsuit after dropping planned $375M Bardy Diagnostics deal

Hillrom faces lawsuit after dropping planned $375M Bardy Diagnostics deal

Hillrom is calling off a planned acquisition of cardiac monitor-maker Bardy Diagnostics, saying the closing conditions of the deal had not been satisfied. The Chicago-based medical technology company announced its decision on Monday after Medicare Administrative Contractor Novitas Solutions slashed

Read More Hillrom faces lawsuit after dropping planned $375M Bardy Diagnostics deal